| Zacks Company Profile for VAXART, INC. (VXRT : OTC) |
|
|
| |
| • Company Description |
| Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus. Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Francisco, United States.
Number of Employees: 105 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.41 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 655,973 shares |
| Shares Outstanding: 228.96 (millions) |
| Market Capitalization: $93.19 (millions) |
| Beta: 1.32 |
| 52 Week High: $0.98 |
| 52 Week Low: $0.26 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
17.12% |
14.05% |
| 12 Week |
11.20% |
6.59% |
| Year To Date |
-38.53% |
-46.27% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
170 Harbor Way Suite 300
-
South San Francisco,CA 94080
USA |
ph: 650-550-3500
fax: 650-871-8580 |
ir@vaxart.com |
http://www.vaxart.com |
|
|
| |
| • General Corporate Information |
Officers
Steven Lo - Chief Executive Officer and President
Michael J. Finney - Chairman of the Board
Phillip Lee - Chief Financial Officer
Kevin Finney - Director
Elaine J. Heron - Director
|
|
Peer Information
VAXART, INC. (GSAC)
VAXART, INC. (CASI)
VAXART, INC. (ALCD.)
VAXART, INC. (OMNN)
VAXART, INC. (CGPI.)
VAXART, INC. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 92243A200
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/12/25
|
|
Share - Related Items
Shares Outstanding: 228.96
Most Recent Split Date: 2.00 (0.09:1)
Beta: 1.32
Market Capitalization: $93.19 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.07 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.29 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/12/25 |
|
|
|
| |
